αααααβααΎαNZYMB β’ SWX
add
Novozymes A/S
44.68Β CHF
31 ααααΆ, 10:05:00 PM ααααβααα +1 · CHF · SWX · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΆααα»αααααΆααααααααΆααα·ααααΆαααΌααααααααααΆαα
α»ααααααΈαα
CH
αα·αααΈαα»α
44.68Β CHF
α
ααααααα½αααααΆαα
α»αααααα
44.68Β CHF - 44.68Β CHF
ααΎαβαα»αβααΈααααΆα
171.08Β αααΈααΆα DKK
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
CPH
ααααααΆαααΈααααΆα
.INX
0.50%
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
(EUR) | αα·αα»ααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌα | 915.85Β ααΆα | 61.70% |
α
αααΆαααααα·ααααα·ααΆα | 271.75Β ααΆα | 52.62% |
α
αααΌααα»ααα | 31.95Β ααΆα | -60.72% |
ααααΆααα
αααααα»ααα | 3.49 | -75.70% |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | β | β |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | 150.94Β ααΆα | -16.50% |
α’ααααΆαααααααααΆαααααα·αααααΆα | 29.00% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
(EUR) | αα·αα»ααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 260.80Β ααΆα | 85.35% |
ααααααααα»α | 15.25Β αααΈααΆα | 302.43% |
ααΆαααα½ααα»αααααΌαααα»α | 4.25Β αααΈααΆα | 119.23% |
ααΌαβααααα»α | 11.00Β αααΈααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 277.90Β ααΆα | β |
ααααααααααΉαααααα
| 1.13 | β |
ααα
ααααααΎαααααα | 1.83% | β |
ααα
ααααααΎααΎααα»α | 2.15% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
(EUR) | αα·αα»ααΆ 2024info | ααΆαααααΆααααααΌαααΆαβααααΆα |
---|---|---|
α
αααΌααα»ααα | 31.95Β ααΆα | -60.72% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | 264.05Β ααΆα | 74.01% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | -27.45Β ααΆα | 70.98% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -186.70Β ααΆα | -205.10% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 55.55Β ααΆα | 902.56% |
ααα αΌαααΆα
αααααΆααααααα | -17.57Β ααΆα | 68.87% |
α’αααΈ
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange. Wikipedia
CEO
ααΆααααααΎαα‘αΎα
2000
αααααβαααααΆα
αα»ααααα·α
10,452